International Course on Antibiotics and Resistance ICARe, 11-19 Nov 2017

Dear All:

FYI, see below an announcement of an 8-day intensive course in Paris in November 2017: “ICARe is designed for early career scientists – assistant professors, new industry scientists, MDs, and postdoctoral research associates – as well as members from developing areas contending with the practical challenge of managing the antibiotic resistance problem with limited resources. Attendance will be limited to 40 students and will reflect the global nature of the problem.”

Also keep in mind the 6-8 Sep ASM-ESCMID conference in Boston on antibacterial drug development along with its preceding co-sponsored (CARB-X + ASM-ESCMID) workshop. 

–jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust
Follow me on Twitter: @JohnRex_NewAbx


Dear Colleague,

We are organizing the second edition of the International Course on Antibiotics and Resistance (ICARe) which will be held at the Fondation Mérieux, Annecy, France, November 11-19, 2017 (download flyer and course outline here).

The specific goal of ICARe is to bring leaders in academics and industry together with trained scientists at the dawn of their careers. Cutting-edge approaches for understanding and detection of resistance, antibiotic discovery, chemical optimization, and use of strategies that minimize the development of resistance will be examined.

Our course aims at providing future leaders in the field of antibiotics and resistance with the information they do not usually get in graduate or medical school, but that they need to make a serious contribution to solving the problem. In the past, they would receive some of that training once they joined a well-established antibiotic discovery program in pharma.  But more of the needed discoveries now rely on academic researchers with little or no experience, and many are spinning out biotech ideas without really understanding the challenges.

You can use the flyer to advertise for the course and the outline is to incite you to send your most promising collaborators.

Thank you in advance for your help,

P. Courvalin, M. Gilmore, G. Wright

Share

Leaky pipe(line)s, Part 2 / CARB-X reboot / WHO 2021 pipeline review

Dear All, We have a 3-part discussion today on the theme of “I want a new drug … so how do I find it?” Off we go! First, the 14 June 2022 newsletter entitled “Leaky Pipe(lines) / When Is A Molecule A Drug” generated further discussions that are worth sharing: It was noted the microdosing

Antibiotic procurement models for LMICs / G7 Leaders call for Pull!

Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures

Leaky pipe(lines) / When is a molecule a drug? (Part 1 of 2)

Dear All, I was fascinated by this recent paper in AAC: Neha K. Prasad, Ian B. Seiple, Ryan T. Cirz, and Oren S. Rosenberg. Leaks in the Pipeline: a Failure Analysis of Gram-Negative Antibiotic Development from 2010 to 2020. Antimicrob Agents Chemother. 2022 May 17;66(5):e0005422. doi:10.1128/aac.00054-22. (Addendum: This newsletter has a follow-up newsletter.) In brief,

FDA/CVM: Antimicrobial use in companion animals

Dear All, Post-newsletter addendum: I’ve learned that USDA will host a 10 Aug 2022 (virtual, 10a-4.30p ET) workshop on AMR in food agriculture. See the meetings calendar for more details; go here to register. I’ll confess to having missed entirely the request back in February 2022 from FDA’s Center for Veterinary Medicine (CVM) for comments on antimicrobial

Scroll to Top